Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaborated with Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was incorporated in 2012 and is headquartered in Parsippany, New Jersey.

Revenue projections:

Revenue projections for ZTS
Revenue projections for ZTS

ZTS's projected revenue decline from last year is likely to make investors cautious. Lower revenues often hurt a company's bottom line, leading investors to be concerned about the company's ability to maintain profitability and deliver strong financial results in the future.

Financial Ratios:

currentRatio 3.69100
forwardPE 27.39301
debtToEquity 129.44200
earningsGrowth 0.16300
revenueGrowth 0.11000
grossMargins 0.70094
operatingMargins 0.38526
trailingEps 5.32000
forwardEps 6.34000

ZTS's current ratio of 3.691 indicates strong liquidity, meaning the company can comfortably meet its short-term debt obligations. This financial position reflects ZTS's ability to use its cash reserves and current assets to cover liabilities without facing any cash flow issues.
Zoetis Inc.'s Forward PE is in a favorable range, meaning its stock price compares well with its earnings and isn't overpriced. This leaves room for growth, making it a compelling opportunity for investors looking to benefit from potential future gains.
Zoetis Inc.'s high debt-to-equity ratio points to a heavily leveraged company. With more debt than equity, Zoetis Inc. may face increased financial risk, especially if its earnings or cash flow come under pressure.
ZTS's positive earnings and revenue growth signal the company's business is on track for further expansion. These strong financial trends suggest that ZTS will continue to grow its operations, driven by increasing profits and revenue.
With positive gross and operating margins, ZTS's profitability is evident. These metrics suggest the company is efficiently managing its expenses while maintaining strong revenue, highlighting a solid financial foundation.
Zoetis Inc.'s forward EPS is higher than its trailing EPS, suggesting the company is expected to improve its profitability this financial year. This reflects growing confidence in Zoetis Inc.'s earnings potential, with forecasts indicating better financial performance than in the prior year.

Price projections:

Price projections for ZTS
Price projections for ZTS

The price of ZTS has often been situated close to the lower end of projections. This consistent trend may signal difficulties for the company in achieving investor expectations for future performance.

Recommendation changes over time:

Recommendations trend for ZTS
Recommendations trend for ZTS


The recent buy bias for ZTS from analysts signals strong confidence in the stock's potential. This positive sentiment could encourage investors to see ZTS as a smart place to invest their money, especially those looking for stable, long-term returns in a well-established company.